These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19567528)

  • 21. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
    Spinder T; Spijkstra JJ; van den Tweel JG; Burger CW; van Kessel H; Hompes PG; Gooren LJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):151-7. PubMed ID: 2471710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naloxone does not reverse the suppressive effects of testosterone infusion on luteinizing hormone secretion in pubertal boys.
    Kletter GB; Foster CM; Brown MB; Padmanabhan V; Beitins IZ; Marshall JC; Kelch RP
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1241-7. PubMed ID: 1955505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nocturnal naloxone fails to reverse the suppressive effects of testosterone infusion on luteinizing hormone secretion in pubertal boys.
    Kletter GB; Foster CM; Brown MB; Beitins IZ; Marshall JC; Kelch RP
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1147-51. PubMed ID: 7962287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.
    Patel K; Coffler MS; Dahan MH; Yoo RY; Lawson MA; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5456-61. PubMed ID: 14602789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
    George JT; Kakkar R; Marshall J; Scott ML; Finkelman RD; Ho TW; Veldhuis J; Skorupskaite K; Anderson RA; McIntosh S; Webber L
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4313-4321. PubMed ID: 27459523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects of testosterone infusion and naloxone on luteinizing hormone secretion in normal men.
    Kletter GB; Foster CM; Beitins IZ; Marshall JC; Kelch RP
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1215-9. PubMed ID: 1430081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls.
    Venturoli S; Porcu E; Fabbri R; Magrini O; Gammi L; Paradisi R; Flamigni C
    J Clin Endocrinol Metab; 1992 Apr; 74(4):836-41. PubMed ID: 1548348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated Episodic Luteinizing Hormone Release Accompanies Blunted Progesterone Regulation in PCOS-like Female Rhesus Monkeys (Macaca Mulatta) Exposed to Testosterone during Early-to-Mid Gestation.
    Abbott DH; Vepraskas SH; Horton TH; Terasawa E; Levine JE
    Neuroendocrinology; 2018; 107(2):133-146. PubMed ID: 29949806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
    Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA
    Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.